FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours ner response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

																				-
1. Name and Address of Reporting Person*  LAROSA JOSEPH J						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last)	,	irst) LL RIVER ROA	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/16/2022									X Officer (give title Officer (spin below)  EVP General Counsel and Secre					
(Street)	TOWN N	Y	10591		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									S. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting					1
(City)	(S	tate)	(Zip)												Person					
		Tab	le I - Nor	า-Deriv	/ativ	e Se	curities	s Ac	quir	red, D	isp	osed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		e, T	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)					s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code \	/	Amount	(A) o (D)	r Pric	се	Transacti (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock			12/10	12/16/2022				1	A <sup>(1)</sup>		2,752	2 A	\$	0.0	23,110			D		
Common	Stock															2,1	109		1 1	2021 GRAT
Common Stock															5,320				2022 GRAT	
Common Stock															335			I 4	By 401(k) Plan	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution	Date, 1	4. Transaction Code (Instr. 8)		5. Number		Expi	ate Exer iration D nth/Day/	ate		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)			. Price of Perivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form Director Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title	Amou or Numb of Share	er					
Non- Qualified Stock Option (right to buy)	\$726.53	12/16/2022			A		10,159			(2)	12	2/16/2032	Common Stock	10,1	59	\$0.0	10,15	9	D	

## Explanation of Responses:

- 1. Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026.
- 2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/\*\*Joseph LaRosa 12/19/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.